Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: One more try

Excellent point. I am sure also, that J3 was given full access to writing/wordsmithing the PR. Looking at it from your perspective, the settlement dollars will be great but from the PR perspective, J3 shares remain largely unaffected which ensures they don't take a double whammy. I really like that train of thought.

Thanks for sharing.

Share
New Message
Please login to post a reply